Emerging Immunotherapy Approaches for Treating Prostate Cancer

被引:10
|
作者
Meng, Lingbin [1 ]
Yang, Yuanquan [1 ]
Mortazavi, Amir [1 ]
Zhang, Jingsong [2 ]
机构
[1] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USA
关键词
immunotherapy; prostate cancer; immune checkpoint inhibitors; bispecific antibodies; CAR T cells; vaccines; cytokines; immunotherapeutic combinations; CAR-T-CELLS; IMMUNE-CHECKPOINT; DOUBLE-BLIND; PHASE-III; PLUS DOCETAXEL; CLINICAL-TRIAL; SIPULEUCEL-T; TUMOR MICROENVIRONMENT; DNA VACCINE; ANTIGEN;
D O I
10.3390/ijms241814347
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunotherapy has emerged as an important approach for cancer treatment, but its clinical efficacy has been limited in prostate cancer compared to other malignancies. This review summarizes key immunotherapy strategies under evaluation for prostate cancer, including immune checkpoint inhibitors, bispecific T cell-engaging antibodies, chimeric antigen receptor (CAR) T cells, therapeutic vaccines, and cytokines. For each modality, the rationale stemming from preclinical studies is discussed along with outcomes from completed clinical trials and strategies to improve clinical efficacy that are being tested in ongoing clinical trials. Imperative endeavors include biomarker discovery for patient selection, deciphering resistance mechanisms, refining cellular therapies such as CAR T cells, and early-stage intervention were reviewed. These ongoing efforts instill optimism that immunotherapy may eventually deliver significant clinical benefits and expand treatment options for patients with advanced prostate cancer.
引用
收藏
页数:26
相关论文
共 50 条
  • [41] Immunotherapy for Prostate Cancer
    Venturini, Nicholas J.
    Drake, Charles G.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2019, 9 (05):
  • [42] Immunotherapy in Prostate Cancer
    Ilya Sobol
    R. H. Thompson
    Haidong Dong
    Christopher Krco
    Eugene D. Kwon
    Current Urology Reports, 2015, 16
  • [43] Immunotherapy in Prostate Cancer
    Sobol, Ilya
    Thompson, R. H.
    Dong, Haidong
    Krco, Christopher
    Kwon, Eugene D.
    CURRENT UROLOGY REPORTS, 2015, 16 (06) : 1 - 5
  • [44] Immunotherapy for prostate cancer
    Fong L.
    Small E.J.
    Current Urology Reports, 2006, 7 (3) : 239 - 246
  • [45] Immunotherapy in Prostate Cancer
    Panesar, Kiran
    US PHARMACIST, 2016, 41 (08) : HS2 - HS5
  • [46] The immunotherapy of prostate cancer
    AG Dalgleish
    MJA Perry
    JD Eaton
    D Hrouda
    SM Todryk
    RS Kirby
    Prostate Cancer and Prostatic Diseases, 2000, 3 : 303 - 307
  • [47] Prostate cancer immunotherapy
    Mitsogiannis, Iraklis
    Tzelves, Lazaros
    Dellis, Athanasios
    Issa, Hussein
    Papatsoris, Athanasios
    Moussa, Mohammad
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (05) : 577 - 590
  • [48] The immunotherapy of prostate cancer
    Dalgleish, AG
    PROSTATE AND RENAL CANCER, BENIGN PROSTATIC HYPERPLASIA, ERECTILE DYSFUNCTION AND BASIC RESEARCH: AND UPDATE, 2003, : 191 - 194
  • [49] Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient
    Gulley, JL
    Dahut, WL
    UROLOGY, 2003, 62 (6B) : 147 - 154
  • [50] The Emerging Profile of Immunotherapy Approaches in the Treatment of AML
    Daver, Naval
    ONCOLOGY-NEW YORK, 2019, 33 (01): : 28 - 32